[go: up one dir, main page]

WO1999038888A3 - Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production - Google Patents

Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production Download PDF

Info

Publication number
WO1999038888A3
WO1999038888A3 PCT/IT1999/000022 IT9900022W WO9938888A3 WO 1999038888 A3 WO1999038888 A3 WO 1999038888A3 IT 9900022 W IT9900022 W IT 9900022W WO 9938888 A3 WO9938888 A3 WO 9938888A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
production
hcv
protease activity
activity associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT1999/000022
Other languages
English (en)
Other versions
WO1999038888A2 (fr
Inventor
Antonello Pessi
Christian Steinkuehler
Francesco Raffaele De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority to AU25450/99A priority Critical patent/AU2545099A/en
Priority to EP99905173A priority patent/EP1053249A2/fr
Priority to CA002319306A priority patent/CA2319306A1/fr
Priority to JP2000529354A priority patent/JP2002509075A/ja
Publication of WO1999038888A2 publication Critical patent/WO1999038888A2/fr
Publication of WO1999038888A3 publication Critical patent/WO1999038888A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des peptides capables d'inhiber l'activité de la sérine protéase associée à la protéine NS53 du virus de l'hépatite C (VHC), leurs utilisations et leur procédé de production consistant à effectuer la protéolyse de polypeptides contenant au moins une séquence sélectionnée parmi les sites de jonction NS3/NS4A, NS4A/NS4B, NS4B/NS5A et/ou NS5A/NS5B de la polyprotéine du VHC.
PCT/IT1999/000022 1998-02-02 1999-02-02 Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production Ceased WO1999038888A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU25450/99A AU2545099A (en) 1998-02-02 1999-02-02 Peptide inhibitors of the serine protease activity associated to the ns3 proteinof hcv, relevant uses and process of production
EP99905173A EP1053249A2 (fr) 1998-02-02 1999-02-02 Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production
CA002319306A CA2319306A1 (fr) 1998-02-02 1999-02-02 Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production
JP2000529354A JP2002509075A (ja) 1998-02-02 1999-02-02 Ｈｃｖのｎｓ３タンパク質に関連したセリンプロテアーゼ活性のペプチド阻害剤、関連する使用およびその製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT98RM000061A IT1299134B1 (it) 1998-02-02 1998-02-02 Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
ITRM98A000061 1998-02-02

Publications (2)

Publication Number Publication Date
WO1999038888A2 WO1999038888A2 (fr) 1999-08-05
WO1999038888A3 true WO1999038888A3 (fr) 1999-10-07

Family

ID=11405519

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT1999/000022 Ceased WO1999038888A2 (fr) 1998-02-02 1999-02-02 Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production

Country Status (6)

Country Link
EP (1) EP1053249A2 (fr)
JP (1) JP2002509075A (fr)
AU (1) AU2545099A (fr)
CA (1) CA2319306A1 (fr)
IT (1) IT1299134B1 (fr)
WO (1) WO1999038888A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
US8871904B2 (en) 2005-08-19 2014-10-28 Vertex Pharmaceuticals Incorporated Processes and intermediates

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
GB9925955D0 (en) * 1999-11-02 1999-12-29 Angeletti P Ist Richerche Bio Hcv n33 protease inhibitors
KR100828453B1 (ko) 2001-01-22 2008-05-13 머크 앤드 캄파니 인코포레이티드 Ｒｎａ 의존성 ｒｎａ 바이러스 폴리머라제의억제제로서의 뉴클레오시드 유도체
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
EP1497282A2 (fr) 2002-04-11 2005-01-19 Vertex Pharmaceuticals Incorporated Inhibiteurs de la serine protease, notamment de la protease ns3-ns4a du virus de l'hepatite c
ATE503764T1 (de) 2002-05-20 2011-04-15 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
ES2315568T3 (es) 2002-05-20 2009-04-01 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido.
ES2350201T3 (es) 2002-05-20 2011-01-20 Bristol-Myers Squibb Company Sulfamidas heterocíclicas como inhibidores del virus de la hepatitis c.
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
PT1654261E (pt) 2003-05-21 2008-01-18 Boehringer Ingelheim Int Compostos inibidores da hepatite c
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CN1856502A (zh) 2003-09-22 2006-11-01 贝林格尔.英格海姆国际有限公司 抗c型肝炎病毒活性的巨环肽
EP2361925A1 (fr) 2003-10-10 2011-08-31 Vertex Pharmaceuticals Incorporated Inhibiteurs de sérine protéases, en particulier la HCV NS3-NS4A protéase
AU2004281780B2 (en) 2003-10-14 2009-03-19 F. Hoffmann-La Roche Ltd Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
EP1944042A1 (fr) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinaisons pour le traitement HCV
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP4682155B2 (ja) 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
EP1711515A2 (fr) 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a
AU2005254057B2 (en) 2004-06-15 2011-02-17 Isis Pharmaceuticals, Inc. C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
CN1972696B (zh) 2004-06-24 2010-08-11 默沙东公司 用于治疗rna依赖性rna病毒感染的核苷氨基磷酸芳基酯
ATE512971T1 (de) 2004-07-20 2011-07-15 Boehringer Ingelheim Int Peptidanaloga als hepatitis c-hemmer
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
EP1781690B1 (fr) * 2004-08-27 2011-06-29 ChronTech Pharma AB Modele de souris transgenique du virus de l'hepatite c (hcv) et identification de therapeutiques du hcv
WO2006109196A2 (fr) * 2005-02-04 2006-10-19 Tripep Ab Modeles de souris transgeniques du virus de l'hepatite c (vhc) et identification des therapies pour le vhc
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
EP2305695A3 (fr) 2005-07-25 2011-07-27 Intermune, Inc. Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C
AU2006275605B2 (en) 2005-08-01 2011-01-06 Merck Sharp & Dohme Corp. Macrocyclic peptides as HCV NS3 protease inhibitors
AU2006275413B2 (en) 2005-08-02 2012-07-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
JP2009513564A (ja) 2005-08-09 2009-04-02 メルク エンド カムパニー インコーポレーテッド Ｒｎａ依存性ｒｎａウイルス感染の治療用のリボヌクレオシド環状アセタール誘導体
ES2344156T3 (es) 2005-08-19 2010-08-19 Vertex Pharmaceuticals Incorporated Procedimientos e intermedios.
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
WO2007044893A2 (fr) 2005-10-11 2007-04-19 Intermune, Inc. Composés et méthodes pour l'inhibition de la réplication du virus de l'hépatite c
RU2008123606A (ru) 2005-11-11 2009-12-20 Вертекс Фармасьютикалз, Инк (Us) Варианты вируса гепатита с
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
EP1886685A1 (fr) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
AU2007309546A1 (en) 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
WO2008051475A2 (fr) 2006-10-24 2008-05-02 Merck & Co., Inc. Inhibiteurs de la protéase ns3 du vhc
WO2008051514A2 (fr) 2006-10-24 2008-05-02 Merck & Co., Inc. Inhibiteurs de la protéase ns3 du hcv
WO2008057208A2 (fr) 2006-10-27 2008-05-15 Merck & Co., Inc. Inhibiteurs de protéase ns3 du vhc
MY164469A (en) 2006-10-27 2017-12-15 Msd Italia Srl Hcv ns3 protease inhibitors
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2121707B1 (fr) 2006-12-20 2012-12-05 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Indoles antiviraux
CN101815533A (zh) 2007-05-04 2010-08-25 弗特克斯药品有限公司 用于治疗hcv感染的组合治疗
MX2009013827A (es) 2007-06-29 2010-03-01 Gilead Sciences Inc Compuestos antivirales.
SG182979A1 (en) 2007-06-29 2012-08-30 Gilead Sciences Inc Antiviral compounds
WO2009010785A1 (fr) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Dérivés macrocycliques d'indole pour le traitement des infections d'hépatite c
CA2699891C (fr) 2007-07-19 2013-10-22 Nigel Liverton Composes macrocycliques servant d'agents antiviraux
WO2009033681A2 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
AU2009241445A1 (en) 2008-04-28 2009-11-05 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
JP4920797B2 (ja) 2008-07-22 2012-04-18 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤としてのマクロ環式キノキサリン化合物
WO2010082050A1 (fr) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Composés benzoxazocines substitués 7-aminoalkyle macrocycycliques destinés au traitement des infections par hépatite c
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
WO2011014487A1 (fr) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Inhibiteurs de protéase ns3 du virus de l'hépatite c
WO2012107589A1 (fr) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
US20140356325A1 (en) 2012-01-12 2014-12-04 Ligand Pharmaceuticals Incorporated Novel 2'-c-methyl nucleoside derivative compounds
WO2014121417A1 (fr) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
WO2014121418A1 (fr) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs méthodes d'utilisation pour le traitement de l'hépatite c

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008304A2 (fr) * 1995-08-22 1997-03-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Methode de production, de purification et d'analyse de polypeptides par l'activite proteolytique de la vhc ns3 protease
WO1997043310A1 (fr) * 1996-05-10 1997-11-20 Schering Corporation Inhibiteurs synthetiques de la protease ns3 du virus de l'hepatite c
WO1999007733A2 (fr) * 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Peptides inhibiteurs de l'hepatite c

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008304A2 (fr) * 1995-08-22 1997-03-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Methode de production, de purification et d'analyse de polypeptides par l'activite proteolytique de la vhc ns3 protease
WO1997043310A1 (fr) * 1996-05-10 1997-11-20 Schering Corporation Inhibiteurs synthetiques de la protease ns3 du virus de l'hepatite c
WO1999007733A2 (fr) * 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Peptides inhibiteurs de l'hepatite c

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GRAKOUI E.A.: "Characterization of the HCV-encoded serine proteinase", J.VIROL., vol. 67, no. 5, 1993, pages 2832 - 2843, XP002111520 *
INGALLINELLA E A: "Potent peptide inhibitors of human HCV NS3 protease are obtained by optimizing the cleavage products", BIOCHEMISTRY, vol. 37, 23 June 1998 (1998-06-23), pages 8906 - 8914, XP002086572, ISSN: 0006-2960 *
LANDRO E.A.: "Mechanistic role of an NS4A cofactor with the truncated NS3 protease of HCV", BIOCHEMISTRY, vol. 36, no. 31, 1997, EASTON, PA US, pages 9340 - 9348, XP002111518 *
LLINAS-BRUNET M ET AL: "Peptide-based inhibitors of the hepatitis C virus serine protease", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, no. 13, 7 July 1998 (1998-07-07), pages 1713-1718, XP004137115, ISSN: 0960-894X *
TOKITA E.A.: "HCV variants from Jakarta, Indonesia classifiable into novel genotypes in the second (2e and 2f) and eleventh (11a) genetic groups.", J.GEN.VIROL., vol. 77, 1996, pages 293 - 301, XP002111519 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
US8871904B2 (en) 2005-08-19 2014-10-28 Vertex Pharmaceuticals Incorporated Processes and intermediates

Also Published As

Publication number Publication date
AU2545099A (en) 1999-08-16
IT1299134B1 (it) 2000-02-29
ITRM980061A1 (it) 1999-08-02
CA2319306A1 (fr) 1999-08-05
ITRM980061A0 (it) 1998-02-02
EP1053249A2 (fr) 2000-11-22
JP2002509075A (ja) 2002-03-26
WO1999038888A2 (fr) 1999-08-05

Similar Documents

Publication Publication Date Title
WO1999038888A3 (fr) Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production
DE122012000004I1 (de) Peptide als inhibitoren der NS3-Serinprotease des hepatitis c virus.
Llinàs-Brunet et al. Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease
ATE277945T1 (de) Makrozyklische peptide als hepatitis c virus ns3 protease inhibitore
DE60138567D1 (de) Diarylrest entfassende peptide als inhibitoren des ns-3 serinproteases von hepatitis c virus
NO991832L (no) Inhibitorer for serin-proteaser, spesielt hepatitt - C - virus NS3-protease
NZ503263A (en) Hepatitis C NS3 protease inhibitor peptides and peptide analogues
NO20030271D0 (no) Nye peptider som NS3-serinproteaseinhibitorer for hepatitt C- virus
Butkiewicz et al. Enhancement of hepatitis C virus NS3 proteinase activity by association with NS4A-specific synthetic peptides: identification of sequence and critical residues of NS4A for the cofactor activity
AU1416099A (en) Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide
IL176237A0 (en) Inhibitors of hepatitis c virus ns3/ns4a serine protease
ATE469914T1 (de) Peptide als hemmer der serinprotease des hepatitis c virus
HUP0302957A2 (hu) Hepatitis C vírus alkil- és aril-alanin P2 csoportokat tartalmazó makrociklusos NS-3 szerin proteáz inhibitorai
WO2004111082A3 (fr) Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
PL373399A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
NO20024797L (no) Makrosykliske NS3-serinproteaseinhibitorer for hepatitt C- virus, som omfatter N-sykliske P2-rester
ATE423127T1 (de) Peptidinhibitoren der ns3-protease des hepatoitis c virus
Narjes et al. Recent developments in the discovery of hepatitis C virus serine protease inhibitors–towards a new class of antiviral agents?
Kakiuchi et al. Non-peptide inhibitors of HCV serine proteinase
SI0932617T1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
CA2365262A1 (fr) Systeme a base de cellules de remplacement et procede de dosage de l'activite de la protease ns3 du virus de l'hepatite c
TW200513260A (en) Hepatitis C virus derived peptides
Fischmann et al. Peptidic inhibitors of the hepatitis C virus serine protease within non-structural protein 3
ATE542140T1 (de) Nichtstrukturelle hcv-proteinmutanten und verwendungsmöglichkeiten dafür
KR980002263A (ko) C형 간염 바이러스의 프로테아제의 활성을 측정할 수 있는 c형 간염 대체 바이러스, 그 재조합 유전자 및 그 용도

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN IL JP KR MX NO NZ US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN IL JP KR MX NO NZ US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2319306

Country of ref document: CA

Ref country code: CA

Ref document number: 2319306

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09601516

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 25450/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999905173

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999905173

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999905173

Country of ref document: EP